BDX vs EW: fair value comparison
Becton, Dickinson and Company and Edwards Lifesciences Corporation · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EW currently sits closer to the top of our ranking by discount to fair value. EW carries the stronger quality grade.
| BDX | EW | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $183.75 | $85.21 |
| 12-month range | $138.67–$193.76 | $75.87–$95.18 |
| Rank by discount to fair value | #38 of 108 Healthcare | #33 of 108 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: BDX fair value analysis · EW fair value analysis